ImStem Appoints new CEO
FARMINGTON, CT, USA, September 2, 2022 /EINPresswire.com/ — ImStem Biotechnology, a scientific stage biotechnology firm centered on stem cell primarily based regenerative mobile therapies to deal with critical ailments with excessive unmet wants, introduced immediately the appointment of Rami Levin as Chief Executive Officer.
Mr. Levin is a seasoned biotech chief with over 26 years of expertise in central nervous system problems and uncommon ailments. Mr. Levin most lately served as the President and Chief Executive Officer of Saniona, a clinical-stage biopharmaceutical firm centered on discovering, creating, and commercializing revolutionary therapies for uncommon illness sufferers. While at Saniona, he constructed the corporate’s company workplace and employed the manager group within the U.S. and raised important quantity of capital to advance its scientific packages. Prior to becoming a member of Saniona, Mr. Levin was the President of Sobi Inc., the North American affiliate of Sobi, the place he constructed and led the group from infancy to a group of over 300 workers and generated over half a billion USD in annual income. Mr. Levin’s expertise in mergers and acquisitions resulted within the profitable acquisitions of Gamifant®, the primary FDA authorized remedy for major hemophagocytic lymphohistiocytosis (pHLH), and Synagis, the one FDA authorized prophylaxis for respiratory syncytial virus (RSV). Prior to Sobi Inc., Mr. Levin held business management roles of accelerating strategic significance for 18 years at Merck Serono and Schering AG.
We are very excited to welcome Rami to ImStem as our CEO, a job to which he brings years of extremely related expertise for the persevering with growth of the corporate. Rami has a confirmed monitor document in lots of areas crucial to ImStem, together with CNS indications, Multiple Sclerosis, uncommon ailments, capital raises and constructing organizations. Rami is a perfect match for ImStem,” stated Michael Men, Chairman of the Board of Directors of ImStem Biotechnology, Inc.
“I am very honored to be taking on this tremendously exciting role with ImStem and overseeing the next stage in the company’s development,” stated Rami Levin. “This is an important moment in the growth of ImStem, as it aims to revolutionize how serious diseases with significant unmet needs are potentially treated with regenerative and cellular therapies.”
Mr. Levin earned his MBA from the Recanati Business School at Tel Aviv University in Israel, majoring in International Marketing and has a BSc in Biology from Tel Aviv University.
About Imstem Biotechnology:
ImStem Biotechnology, Inc. aspires to revolutionize how critical ailments with important unmet wants are doubtlessly handled with a brand new technology of regenerative and mobile therapies. Pioneering analysis led to the proprietary state-of-the-art pluripotent stem cell know-how, enabling off-the-shelf, allogeneic stem cell-derived merchandise to be manufactured at scale, differentiating itself from the standard challenges imposed by autologous grownup cell remedy merchandise. The firm’s mission is to advance the science and understanding of human pluripotent stem cell primarily based regenerative mobile therapies via novel and artistic growth pathways and to satisfy unmet medical wants in critical ailments. Its growth technique focuses on neurologic, autoimmune, degenerative, and uncommon orphan ailments.
For extra info, go to: www.imstem.com.
Investor Relations
IMSTEM BIOTECHNOLOGY, INC.
+1 8602817836
e mail us right here
